ArticleFolia microbiologica2025
Lipopolysaccharide of Klebseilla pneumoniae as a potential vaccine target: extraction, purification and structural insights.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klebseilla pneumoniae, poses a major health concern and its lipopolysaccharide act as a potential immunogenic target for vaccine production. The study was aimed to extract, characterize and structural analysis of lipopolysaccharide from local clinical isolate of Klebseilla pneumoniae by using different analytical techniques. In January 2024 due to large number of pneumonia infections, clinical sample of Klebseilla pneumoniae was collected from tertiary care hospitals of Punjab, Pakistan. Bacterial strain was characterized and antibiotic testing was performed using disk diffusion method. Lipopolysaccharide was extracted, quantified and characterized by various analytical methods such as Limulus Amebocyte Lysate (LAL) assay, SDS-PAGE, High Performance Liquid chromatography (HPLC), Fourier Transfer Infrared spectroscopy (FTIR) and Gas Chromatography-Mass Spectroscopy (GC-MS). Results showed that Klebseilla pneumoniae had highest resistant to most β-lactams and aminoglycosides whereas less sensitive to colistin, merpenem and imipenem. Hot phenol-water method yields purified lipopolysaccharide that was further confirmed by SDS-PAGE that demonstrated O-polysaccharide and lipid A moiety. While HPLC revealed 80-90% purity compared with commercial standard. FTIR spectrum showed distinctive peaks at 3331.10 cm⁻¹, 2216.21 cm⁻¹, 1982.82 cm⁻¹, and 667.37 cm⁻¹, corresponding to hydroxyl, alkyne/nitrile, carbon bonds, and pyranose ring structures, which revealed sugar moieties such as glucosamine that are key components of lipid A in lipopolysaccharide whereas GC-MS detected vital immunogenic components phenylephrine, 1-adamantane methylamine and α-bisabolol. It is concluded that lipopolysaccharide isolated from local isolate of K. pneumoniae represented the structurally validated and immunologically active biomolecules, act as a potential vaccine candidate to address antimicrobial resistance in developing countries.
Indexed as
Identifiers
41452450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.